Most Popular
-
1
Korean labor force to shrink by 10 million by 2044: report
-
2
[AtoZ Korean Mind] Does your job define who you are? Should it?
![[AtoZ Korean Mind] Does your job define who you are? Should it?](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/06/20240506050099_0.jpg&u=)
-
3
Allegations surrounding BTS resurface, enraged fans demand apology
-
4
Students with history of violence will be barred from becoming teachers
-
5
Top prosecutor pledges 'speedy, strict' probe into first lady's luxury bag allegations
![[AtoZ Korean Mind] Does your job define who you are? Should it?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/06/20240506050099_0.jpg&u=)
SK Inc.'s European bio subsidiary Yposkesi has begun the construction of its second drugmaking plant in France to ramp up its manufacturing capacity, the holding firm of South Korea's No. 3 conglomerate SK Group said Monday.
In March, SK acquired a 70 percent stake in Yposkesi, a France-based Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, to expand its presence in the burgeoning biologic CMO market.
The latest deal is SK Inc.'s third acquisition in the global CMO sector after taking over global drugmakers such as Bristol Myers Squibb in 2017 and AMPAC in 2018.
Yposkesi is investing $71 million to double its production space in its existing facility near Paris to 10,000 square meters, which would become one of the largest advance therapy medicinal products facilities in Europe, the Korean firm said.
The second plant is scheduled to come online in 2023 after receiving approval from drug safety regulators in Europe and the United States, to better meet rising manufacturing demand from its clients, SK said. (Yonhap)
In March, SK acquired a 70 percent stake in Yposkesi, a France-based Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, to expand its presence in the burgeoning biologic CMO market.
The latest deal is SK Inc.'s third acquisition in the global CMO sector after taking over global drugmakers such as Bristol Myers Squibb in 2017 and AMPAC in 2018.
Yposkesi is investing $71 million to double its production space in its existing facility near Paris to 10,000 square meters, which would become one of the largest advance therapy medicinal products facilities in Europe, the Korean firm said.
The second plant is scheduled to come online in 2023 after receiving approval from drug safety regulators in Europe and the United States, to better meet rising manufacturing demand from its clients, SK said. (Yonhap)
![[K-pop's dilemma] Is Hybe-Ador conflict a case of growing pains?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/05/07/20240507050746_0.jpg&u=)